Compare AUROW & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUROW | BBIO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 15.9B |
| IPO Year | 2021 | 2019 |
| Metric | AUROW | BBIO |
|---|---|---|
| Price | $0.06 | $74.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 25 |
| Target Price | N/A | ★ $86.33 |
| AVG Volume (30 Days) | 27.8K | ★ 1.9M |
| Earning Date | 04-30-2025 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.35 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,000,000.00 | ★ $502,076,000.00 |
| Revenue This Year | N/A | $89.45 |
| Revenue Next Year | N/A | $73.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $0.05 | $48.78 |
| 52 Week High | $0.87 | $93.42 |
| Indicator | AUROW | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.66 | 32.21 |
| Support Level | N/A | $70.65 |
| Resistance Level | $0.25 | $79.13 |
| Average True Range (ATR) | 0.02 | 2.03 |
| MACD | -0.00 | -0.74 |
| Stochastic Oscillator | 4.90 | 11.90 |
Aurora Innovation is a US autonomous driving provider for heavy trucks. The company produces and sells its Aurora Driver system, which includes hardware installed in a vehicle, software to autonomously drive it, and data management to maintain and improve the software. Aurora targets long-haul routes. The company currently offers its trucking-as-a-service model, where it owns and operates the trucks and makes deliveries for customers. The company plans to start selling its driver-as-a-service model next year, where fleet owners will own the trucks and Aurora's software will operate them.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.